Bone Biologics Corp (BBLG) Financial Statements
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Net income was -$3.1M, or -$2.65 per diluted share. Operating activities generated -$2.7M of cash, leaving -$2.7M of free cash flow. At fiscal year end, Bone Biologics held $5.8M in total assets against $418,587 in total liabilities.
Open the full interactive Bone Biologics financials → Quarterly statements, key ratios, valuation history and price charts.
Bone Biologics Key Stats
| Share Price | $0.43 |
|---|---|
| Market Cap | $772,605 |
| 52-Week Range | $0.43 – $2.66 |
| Shares Outstanding | 1.8 million (basic, 2026 Q2) |
Bone Biologics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.07B | — | — | — | — | — |
| Operating Income | -$825,014 | -$1.1M | -$3.7M | -$9.4M | -$4.2M | -$3.2M |
| Pre-Tax Income | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
| Income Tax | $1,600 | $1,600 | — | — | — | — |
| Net Income | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
| Diluted EPS | -$360.00 | -$504.00 | — | -$204.06 | -$28.98 | -$2.65 |
Bone Biologics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$666,737 | -$684,643 | -$765,988 | -$773,702 |
| Diluted EPS | -$0.37 | -$0.58 | -$0.43 | -$0.43 |
Bone Biologics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $6.7M | — | — | — | — |
| Current Assets | — | — | — | $3.7M | $3.9M | $5.8M |
| Total Assets | $0 | $6.7M | $8.5M | $3.7M | $3.9M | $5.8M |
| Current Liabilities | $13.7M | — | $2.5M | $831,402 | $377,712 | $418,587 |
| Total Long-Term Debt | $11.7M | — | — | — | — | — |
| Total Liabilities | $13.7M | $99,909 | $2.5M | $831,402 | $377,712 | $418,587 |
| Shareholders' Equity | -$13.7M | $6.6M | $5.9M | $2.9M | $3.5M | $5.4M |
Bone Biologics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$426,933 | -$1.2M | -$3.6M | -$9.6M | -$4.1M | -$2.7M |
| Cash From Financing | $402,788 | $7.9M | $4.4M | $5.0M | $4.4M | $4.7M |
| Free Cash Flow | — | — | — | -$9.6M | -$4.1M | -$2.7M |
Figures from Bone Biologics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bone Biologics financials page for every line item.
Bone Biologics Company Profile
| Ticker | BBLG |
|---|---|
| Exchange | Nasdaq |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| Headquarters | Burlington, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001419554 |
Frequently Asked Questions
What was Bone Biologics' net income in fiscal 2025?
Bone Biologics reported net income of -$3.1M for fiscal 2025.
What was Bone Biologics' earnings per share (EPS) in fiscal 2025?
Bone Biologics' diluted EPS was -$2.65 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bone Biologics generate in fiscal 2025?
Bone Biologics generated -$2.7M of free cash flow in fiscal 2025.
How many shares of Bone Biologics are outstanding?
Bone Biologics reported a weighted average of 1.8 million basic shares outstanding in 2026 Q2.
What is Bone Biologics' market cap?
Based on its latest closing price, Bone Biologics (BBLG) has a market capitalization of about $772,605.
When does Bone Biologics' fiscal year end?
Bone Biologics' fiscal year end, as registered with the SEC, is December 31.
Where is Bone Biologics headquartered?
Bone Biologics lists its business address in Burlington, Massachusetts in its SEC filings.